HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290 | Completed Phase 1 Results DMC FDA Drug

• 2 other identifiers: 1436-00012019-004432-28
• Study Type: interventional
• Target: 45
• Locations: 2 countries
• Sites: 19

Brief Summary

This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study. The laser treatment is called panretinal photocoagulation. The purpose of the study is to find out how well different doses of a medicine called BI 764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first part, participants get different doses of BI 764524 only once. Participants are in the first part for about 5 months and visit the study site about 8 times. In the second part, participants are put into different groups by chance. Some participants get BI 764524 injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham injection means that it is not a real injection and contains no medicine. Participants cannot tell whether they get the real injection or a sham injection. For the second part, participants are in the study for about 7 months. During this time, they visit the study site about 7 times. In this study, BI 764524 is given to humans for the first time. The doctors compare how well people tolerate the BI 764524 injections and the sham injections. The doctors also regularly check the general health of the participants.

Conditions

Diabetic Retinopathy

Outcome Measures

Primary Outcomes (2)

• Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8

  Single-rising dose (SRD) part - The number of patients with dose limiting events (DLEs) from drug administration until Day 8 (7 days after treatment).

  From drug administration (day 1) till day 8, Up to 7±2 days.

• Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.

  Multiple dosing (MD) part - the number of patients with drug-related Adverse Events (AEs) from drug administration until End of Trial.

  From drug administration (day 1) till End of Trial, up to 23 weeks.

Secondary Outcomes (17)

• SRD Part - Number of Patients With Drug-related Adverse Events at End of Trial

  From drug administration (day 1) till End of Trial, up to 15 weeks.

• SRD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

  From drug administration (day 1) till End of Trial, up to 15 weeks.

• MD Part - Number of Patients With Ocular Adverse Events (Eye Disorders) at End of Trial

  From drug administration (day 1) till End of Trial, up to 23 weeks.

• MD Part - Change From Baseline of the Size of the FAZ in FTR at Visit 5

  Baseline (day 0) and Visit 5 (day 85±7).

• MD Part - Change From Baseline of the Size of the FAZ in SVC at Visit 5

  Baseline (day 0) and Visit 5 (day 85±7).

Study Arms (5)

Single-rising dose part - low dose BI 764524

EXPERIMENTAL

Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of low dose BI 764524.

Drug: BI 764524

Single-rising dose part - medium dose BI 764524

EXPERIMENTAL

Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of medium dose BI 764524.

Drug: BI 764524

Single-rising dose part - high dose BI 764524

EXPERIMENTAL

Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received one intravitreal injection of high dose BI 764524.

Drug: BI 764524

Multiple dosing part - Sham

SHAM COMPARATOR

Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three sham intravitreal injections, each separated by 4 weeks.

Drug: Sham control of BI 764524

Multiple dosing part - high dose BI 764524

EXPERIMENTAL

Pan-retinal photocoagulation (PRP)-treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischaemia (DMI) received three intravitreal injections of high dose BI 764524, each separated by 4 weeks.

Drug: BI 764524

Interventions

BI 764524 DRUG

BI 764524

Multiple dosing part - high dose BI 764524; Single-rising dose part - high dose BI 764524; Single-rising dose part - low dose BI 764524; Single-rising dose part - medium dose BI 764524

Sham control of BI 764524 DRUG

Sham control of BI 764524

Multiple dosing part - Sham

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Single rising dose (SRD) and multiple dosing (MD) part:
• Pan-retinal photo coagulation treated proliferative diabetic retinopathy (PDR) participants with either no or inactive retinal neovascularization per investigator judgement in the study eye
• Male or female participants of age ≥ 18 years
• HbA1c of ≤ 12.0%
• Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use two methods of contraception with at least one of them being a highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the clinical trial protocol.
• A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 2 years without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 2 years of menorrhea, a single FSH measurement is sufficient.
• Signed and dated written informed consent in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH GCP) and local legislation prior to admission to the trial
• SRD part only:
• Evidence of diabetic macular ischemia (DMI) per investigator´s judgement, defined as any degree of disruption of retinal vascularity in superficial and/or deep retinal plexus in OCTA
• Best-corrected Visual activity (VA) in the non-study eye better than best-corrected VA in the study-eye, if both eyes are eligible and have identical VA the investigator may select the study eye.
• Best-corrected VA ≤55 letters (20/80) or worse
• MD part only:
• Presence of significant DMI: large foveal avascular zone defined as those with ≥0.5mm2 area in superficial vascular complex (SVC) present on optical coherence tomography angiography. If FAZ is \<0.5mm2 then enlarged peri-foveal inter-capillary space in at least 1 quadrant will be sufficient.
• If both eyes are eligible, the investigator may select either eye to be the study eye.
• Best-corrected VA ≤ 85 letters (20/20) or worse

You may not qualify if:

• SRD part only:
• Participants receiving intravitreal (IVT) injections for active diabetic macular edema (DME, injections: anti-vascular endothelial growth factor (VEGF), steroids) and macular laser in the study eye in the previous 3 months prior to enrolment
• Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the previous 3 months prior to enrolment
• Current or planned use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol)
• Additional eye disease in the study eye that could compromise best corrected VA (BCVA) with visual field loss, uncontrolled glaucoma (IOP\>24), age related macular degeneration, history of ischemic optic neuropathy or retinal vascular occlusion, symptomatic vitreomacular traction, or genetic disorders such as retinitis pigmentosa; history of high myopia \> 8 diopters in the study eye. Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation with SD-OCT
• Any intraocular surgery in the study eye within 3 months prior to screening
• Aphakia or total absence of the posterior capsule. Yttrium aluminium garnet (YAG) laser capsulotomy in the study eye if performed less than 3 months prior to enrolment
• Participants not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator´s opinion, makes the patient an unreliable trial participant)
• Previous participation in this trial or in other trials with IVT injections administered within 3 months.
• MD part only:
• DME, defined as a central subfield thickness (CST) ≥305 micrometer (μm) for men and ≥290 μm women measured with optovue (Optical coherent tomography) OCT in the study eye
• Participants receiving IVT injections for active DME (anti-VEGF, steroids) and macular laser in the study eye in the previous 3 months prior to enrolment
• Participants receiving anti-VEGF IVT injections for active PDR in the study eye in the previous 3 months prior to enrolment
• Heavily lasered macula in the study eye per investigator's judgement
• History of vitrectomy in the study eye

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (19)

Trinity Research

Dothan, Alabama, 36301, United States

Location

Retina-Vitreous Associates Medical Group

Beverly Hills, California, 90211, United States

Location

Stanford University Medical Center

Palo Alto, California, 94303, United States

Location

Florida Retina Institute

Orlando, Florida, 32806, United States

Location

Raj K. Maturi, MD PC

Carmel, Indiana, 46290, United States

Location

Joslin Diabetes Center

Boston, Massachusetts, 02115, United States

Location

Long Island Vitreoretinal Consultants

Great Neck, New York, 11021, United States

Location

New York Eye and Ear Infirmary of Mount Sinai

New York, New York, 10003, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Austin Research Center for Retina, PLLC

Austin, Texas, 78705, United States

Location

Retina Consultants of Texas

Bellaire, Texas, 77401, United States

Location

Valley Retina Institute, PA

McAllen, Texas, 78503, United States

Location

Retina Consultants of Texas

The Woodlands, Texas, 77384, United States

Location

Bradford Royal Infirmary

Bradford, BD9 6RJ, United Kingdom

Location

Bristol Eye Hospital

Bristol, BS1 2LX, United Kingdom

Location

Southend University Hospital

Essex, SS0 0RY, United Kingdom

Location

Gloucestershire Royal Hospital

Gloucester, GL1 3NN, United Kingdom

Location

Moorfields Eye Hospital

London, EC1V 2PD, United Kingdom

Location

Sunderland Eye Infirmary

Sunderland, SR2 9HP, United Kingdom

Location

Related Publications (1)

• Chong V, Nguyen QD, Sepah Y, Giani A, Pearce E. HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol. Trials. 2022 Aug 17;23(1):669. doi: 10.1186/s13063-022-06527-y.

  PMID: 35978329 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Diabetic Retinopathy

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Results Point of Contact

• Title: Boehringer Ingelheim, Call Center
• Organization: Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: This trial will consist of an single rising dose (SRD) part followed by an multiple dosing (MD) part. SRD part will be nonrandomized, open-label, and uncontrolled. MD part will be single-masked, randomized and sham-controlled (Ratio 2:1). Parties masked in the MD part are participant and masked site staff (including investigator). The Intervention model in the MD part is active group versus sham injection (=2 arms).
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2020
• First Posted: June 9, 2020
• Study Start: June 12, 2020
• Primary Completion: April 28, 2023
• Study Completion: April 28, 2023
• Last Updated: May 22, 2024
• Results First Posted: May 22, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

GB (6); US (13)